SLE (Vicky.R)
SLE (Vicky.R)
SLE (Vicky.R)
The child may be at risk for self-esteem or body image with lupus in certain families. In addition, genes on chro-
disturbances because of the limitations imposed by illness mosome 6 called immune-response genes were also associ-
and any physical manifestations. Encourage the child and ated with the disease.
family members to speak openly about the child’s condition SLE is a multisystem autoimmune disease involving
and to feel comfortable asking others for assistance when both the humoral and cellular aspects of the innate and
needed. Support organizations can provide educational acquired immune systems. The autoimmune reactions are
materials, specialized services, and financial aid for qualified directed against the cell nucleus, especially the DNA. Au-
children and their families (see for organiza- toantibodies are produced against the nuclear antigens,
tions). Important measures that promote adaptation to the cytoplasmic antigens, and blood cell surface antigens.
disease and enhance development include encouraging the When the autoantibodies bind to their specific antigens,
child’s natural skills and characteristics to develop. Provide complement activation occurs, and immune complexes
opportunities for the child to reach their maximum poten- accumulate within the blood vessel walls, causing ischemia.
tial while ensuring personal safety and management of their Ischemia within the blood vessels leads to thickening of
condition. the internal lining, fibrinoid degeneration, and thrombus
formation. At this point, manifestations of SLE appear.
Community Care
The child with JA can be managed primarily in the home. Assessment
Clinic, home health, and school nurses are primarily
The manifestations of SLE vary, depending on the
responsible for collaborating with the healthcare team to
organs affected and degree of their involvement. The
monitor and manage the needs of the child with this con-
American College of Rheumatology has established crite-
dition. Issues of impaired physical mobility, altered nutri-
ria of 11 manifestations to distinguish SLE from other
tion, risk for impaired skin integrity, and chronic pain
connective tissue diseases (Chart 20–1). Evidence of four
must be managed on a daily basis. The child also faces
manifestations in the absence of other definable disease
challenges related to altered growth and development,
entities is sufficient for the diagnosis of SLE. Generally,
and the potential for body image disturbances caused by
nonspecific findings that may be assessed at the time of
the debilitating nature and sometimes disfiguring out-
disease onset include fever, malaise, weight loss, recur-
comes of the child’s arthritic condition (see TIP 20–3).
rent abdominal pain, anorexia, and fatigue. Headaches
are present in more than 10% of children at the time of
diagnosis. Conjunctivitis also is a common early
Systemic Lupus Erythematosus (SLE) manifestation.
Arthritis and arthralgia are the most common present-
SLE is a systemic inflammatory disease that affects many ing symptoms of SLE. The child may complain of morn-
organs in the body. Lupus, the Latin term for wolf, was ing stiffness and joint pain or swelling. The arthritis of
combined with erythema to name this disease—lupus SLE is usually symmetric and affects both small and
erythematosus—because one of the presenting symptoms large joints. Commonly affected joints are hands, wrists,
is a facial rash that looks like the face of a wolf. Lupus is and knees. Joint deformities or erosions are rare. Rheu-
an autoimmune disorder that may involve any organ sys- matoid nodules may appear during periods of disease
tem but most commonly involves skin, joints, and kid- exacerbations and may disappear as the disease activity
neys. The onset may be sudden, affecting one or more diminishes.
major organ systems, or it may be insidious in nature, Dermatologic findings are the second most common
with nonspecific symptoms such as fever, fatigue, or joint manifestations. These may include maculopapular and
and muscle pain. When the onset is insidious, diagnosis is vasculitic rashes, livedo reticularis (reddish blue mottling
often delayed for weeks or months. of skin, exacerbated by exposure to cold), and periungual
Childhood SLE accounts for 15% of all cases, affecting erythema or other nail bed changes. Many acutely
approximately 5,000 to 6,000 U.S. children annually. affected individuals may have a butterfly rash across the
The incidence is highest among African American, His- bridge of the nose and on the cheeks that may spread to
panic, and Asian girls. When males are affected they the scalp, neck, chest, and extremities. The rash may
manifest symptoms at an earlier age and have more severe become bullous, possibly leading to a secondary infec-
disease (Adams, MacDermott & Lehman, 2006; Croker & tion. Photosensitivity is a classic dermatologic sign of
Kimberly, 2005). The mortality rate has decreased with SLE, especially if it occurs in the presence of arthritis.
the evolution of newer treatment options. Infection is Other skin eruptions may include vasculitic lesions
currently the leading cause of death. with ulceration; purpuric lesions; and subcutaneous nod-
ules on the palms, fingertips, soles, extremities, or trunk.
Macular and painless ulcerative lesions in the mouth and
Pathophysiology nose may be present. Alopecia, resulting from inflamma-
The cause of SLE is unknown, but genetic, hormonal, tion around the hair follicles, may lead to patchy or gen-
environmental, and immunologic factors are believed to eralized loss of hair. Hair may be coarse, dry, and brittle.
interact and lead to disease expression. Studies indicate Polyserositis, inflammation of several mucous mem-
there is a genetic predisposition to lupus. Genome studies branes, is another clinical manifestation of SLE. Pericardi-
have indicated a gene on chromosome 1 that is associated tis, peritonitis, or pleuritis may be present. Cardiovascular
998 Unit III n n Managing Health Challenges
The diagnosis of systemic lupus erythematosus requires the presence of four or more of the following 11criteria, serially or
simultaneously, during any period of observation.
1. Malar rash: fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds
2. Discold rash: erythematous, raised patches with adherent keratotic scaling and follicular plugging: possibly astrophic
scarring in older lesions
3. Photosensitivity: skin rash as a result of unusual reaction to sunlight, as determined by patient history or physician
observation
4. Oral ulcers: oral or nasopharyngeal ulceration, usually painless, observed by physician
5. Arthritis: nonerosive arthritis involving two or more peripheral joints, characterized by swelling, tenderness, or effusion
6. Serositis: pleuritis, by convincing history of pleuritic pain, rub heard by physician, or evidence of pleural effusion; or
pericarditis documented by electrocardiography, rub heard by physician, or evidence of pericardial effusion
7. Renal disorder: persistent proteinuria, > 500 mg per 24 hour (0.5 g per day) or >3þ if quantitation is not performed;
or cellular casts (may be red blood cell, hemoglobin, granular, tubular, or mixed cellular casts)
8. Neurologic disorder: seizures or psychosis occurring in the absence of offending drugs or known metabolic derange-
ment (e.g., uremia, ketoacidosis, electrolyte imbalance)
9. Hematologic disorder: hemolytic anemia with reticulocytosis; or leukopenia, < 4,000 per mm3 (4.0 3 103 per L) on
two or more occasions; or lymphopenia, < 1,500 per mm3 (1.5 3 103 per L) on two or more occasions; or thrombocy-
topenia, < 100 3 103 per mm3 (100 3 103 per L) in the absence of offending drugs
10. Immunologic disorder: antibody to double stranded DNA antigen (anti-dsDNA) in abnormal titer; or presence of anti-
body to Sm nuclear antigen (anti-Sm); or positive finding of antiphospholipid antibody based on an abnormal serum
level of lgG or lgM anticardiolipin antibodies, a positive test result for lupus anticoagulant using a standard method, of
a false-positive serologic test for syphilis that is known to be positive for at least 6 months and is confirmed by negative
Tieponema pallidum immobilization or fluoresoent treponemal antibody absorption test
11. Antinuclear antibodies: an abnormal antinuclear antibody titer by immunofluoresoence or equivalent assay at any time
and in the absence of drugs known to be associated with drug induced lupus
Adapted with permission from Tan EM, Cohen AS, fries JF, Mast AT, McShane DI, Rothfield NF; et al. The 1982 revised criteria for the classification of
systemic lupus erythematosus, Arthritis Rheum 1982;25:1274, and Hochberg MC. Updating the American College of Rheumatology revised criteria for
the classification of systemic lupus erythematosus [Letter], Arthritis Rheum 1997;40:1725.
symptoms that may develop over time include pericarditis, headache, lethargy, dizziness, seizures, ataxia, and halluci-
substernal or precordial pain, murmurs, persistent tachy- nations. Ongoing use of corticosteroids lowers the
cardia, transient dysrhythmias, and pleural and pericardial threshold for seizure activity and may cause personality
effusions. Raynaud’s phenomenon, in which vasoconstric- changes such as depression or euphoria. Depression can
tion causes blanching, cyanosis, and erythema in the toes also occur as a result of learning that one has SLE or
and fingers in response to cold or stress, may be noted. from coping with the issues associated with acute disease
Renal involvement is common in children. Nephrotic activity that limit the child’s activities.
syndrome and acute glomerulonephritis may develop and With SLE, exacerbations and remissions that vary in
are considered life-threatening occurrences. Renal insuf- severity, depending on the particular organ system
ficiency is manifested by weight gain, hypertension, involved, occur. After the first 2 years, the disease only
edema, increased serum creatinine levels, and decreased rarely involves previously unaffected organ systems. Dis-
creatinine clearance. Additionally, urinalysis reveals he- tinguishing the symptoms of disease exacerbation from
maturia, proteinuria, and increased urinary sediment. those of infectious complications may be difficult. Sus-
Almost all children with SLE have one or more hema- pect infection if fever, coughing, shortness of breath,
tologic abnormalities, including anemia, leukopenia, and chest pain, and changes in behavior and visual acuity
thrombocytopenia. Lymphoid involvement may be noted occur until proved otherwise.
in the form of generalized lymphadenopathy and
hepatomegaly.
Central nervous system symptoms may arise as indica-
Diagnostic Tests
tions of the central nervous system vasculitis, as toxic Initial screening for SLE includes the following tests: a
symptoms resulting from the medication regimen, or as complete blood count with differential, ESR, C-reactive
behavioral outcomes of this chronic illness. Central nerv- protein measurement, antinuclear antibody count, and a
ous system vasculitis can lead to irritability, depression, test to detect RF. Additional laboratory values may be
Chapter 20 n n The Child With Altered Musculoskeletal Status 999
determined to rule out other disease processes The anti- gloves, and layered clothes. Also instruct them to avoid
nuclear antibody test identifies the presence of antinuclear tight clothing.
antibodies in the blood. The presence of antinuclear anti- Photosensitivity can be well controlled by using
bodies is a marker of an autoimmune process and is most sunscreens, avoiding sun exposure, and using steroid
commonly seen in SLE. therapy. When the child must be exposed to the sun,
emphasize the importance of using sunscreens that block
Interdisciplinary Interventions both ultraviolet A and B rays (SPF 15 or higher); avoid-
ing long-term exposure; and wearing long-sleeved cloth-
No one treatment for SLE exists; management depends
ing, pants, large-brimmed hats, and sunglasses. Not only
on the manifestations and severity of the disease. Medical
can sun exposure exacerbate the skin rash, but it may also
management is tailored to meet the individual child’s
precipitate systemic exacerbations.
needs, based on organ system involvement and on the se-
verity of inflammation at the time of evaluation. The goal
of therapy is to control both the acute exacerbations of Interventions for Systemic Involvement
the illness and the ongoing chronic disease manifestations
Major organ system involvement in SLE usually necessi-
to enable optimal functioning, to prevent scarring in any
tates the use of corticosteroids. Symptoms such as fever,
organ system, and to prevent intolerable side effects of
skin manifestations, pleuropericarditis, and lymphadenopa-
the therapy. Collaboration among healthcare professio-
thy usually can be effectively treated with low-dose predni-
nals is necessary. Child life specialists in the hospital set-
sone or hydroxychloroquine. Alternate-day steroid therapy
ting and a variety of allied health professionals in
is currently being used to minimize the linear growth and
outpatient settings, including social workers and psychol-
sexual maturation problems associated with steroid use.
ogists, may help the family and child to cope with issues
(e.g., body image concerns related to disease and medica-
tions) in a positive manner.
----------------------------------------------------
KidKare A child with SLE should wear a
Interventions for Joint Involvement MedicAlert bracelet to alert emergency personnel to
his or her dependence on steroids.
Joint involvement, specifically, arthralgias, are usually ----------------------------------------------------
controlled with NSAIDs and antimalarial medications
such as hydroxychloroquine. Aspirin is not recommended, High-dose oral prednisone for a period of 4 to 6 weeks
because the large doses needed may cause liver toxicity. may be indicated for the child with central nervous sys-
tem and renal involvement. Long-term use of high-dose
prednisone is avoided whenever possible because of the
Alert! Ibuprofen has been associated with an aseptic meningitis syn- serious complications (e.g., cataracts, fractures, hyperten-
drome in SLE; therefore, it should not be administered to children with SLE sion, and metabolic disturbances) that may occur. The
(Nguyen, Gal, Ransom, & Carolos, 2004). aim of therapy is to control activity of the disease with
the lowest possible dose of prednisone. To aid in this
process, steroid-sparing agents such as azathioprine,
methotrexate, and hydroxychloroquine may be used.
Medications must be taken daily to maintain adequate
When the child’s condition has been stabilized, the
blood levels. NSAID therapy requires careful monitoring
high-dose steroids are tapered to prevent the negative
of renal function, because these agents decrease glomeru-
effects of sudden medication withdrawal.
lar blood flow and can precipitate acute renal failure in
Instruct parents regarding the need for an ophthalmic
children with SLE.
evaluation for retinal damage within the first 30 to 60
A physical therapy program can be implemented to
days after initiating drug therapy and every 6 months
help the child manage joint pain, enhance ROM, and
thereafter. These evaluations aid in detecting and pre-
prevent injury and contractures. Periods of rest should be
venting macular inflammatory problems.
incorporated into the child’s daily routine, especially dur-
Periodic blood work for evaluating drug toxicity and
ing periods of exacerbation.
disease activity must also be discussed with the patients
and parents.
Sexually active adolescent females need counseling
Interventions for Skin Involvement about birth control and pregnancy. Inform them that
The rash of SLE is generally treated with an antimalarial SLE can become more active with the use of certain oral
drug, preferably hydroxychloroquine. Topical steroids contraceptives and during pregnancy. It is usually recom-
may also be used, if cutaneous involvement is limited. mended that a diaphragm and spermicide be used for
Because hydroxychloroquine carries a risk of retinal dam- birth control because they do not have adverse side
age, an eye examination should be performed every effects that affect the child’s SLE. However, low-dose
6 months in patients receiving this drug. oral contraceptives may be used if the patient is carefully
Rashes and lesions require careful monitoring for signs monitored, especially if compliance with barrier contra-
of infection. In addition, assess the toes and fingers for ception is poor. The fetus is at risk for injury both by the
vascular compromise. Urge the child and parents to keep mother’s disease and by the side effects of the drugs
the extremities warm during cold weather by using socks, required to treat the mother’s disease.
1000 Unit III n n Managing Health Challenges
Developmental
Considerations 20—2
Management Issues for Children With Systemic Lupus Erythematosus